See more : Truist Financial Corporation (TFC-PO) Income Statement Analysis – Financial Results
Complete financial analysis of Poseida Therapeutics, Inc. (PSTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poseida Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SUDARSHAN PHARMA INDUSTRIES LI (SUDARSHAN.BO) Income Statement Analysis – Financial Results
- TSR, Inc. (TSRI) Income Statement Analysis – Financial Results
- Hygeia Healthcare Holdings Co., Limited (6078.HK) Income Statement Analysis – Financial Results
- AURES Technologies S.A. (AURS.PA) Income Statement Analysis – Financial Results
- Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) Income Statement Analysis – Financial Results
Poseida Therapeutics, Inc. (PSTX)
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.70M | 130.36M | 31.24K | 0.00 | 0.00 | 0.00 | 2.99M | 9.77M |
| Cost of Revenue | 156.77M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 0.00 | 0.00 |
| Gross Profit | -92.07M | 125.19M | -4.52M | -2.59M | -1.19M | -689.00K | 2.99M | 9.77M |
| Gross Profit Ratio | -142.29% | 96.03% | -14,472.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 156.77M | 152.90M | 136.73K | 103.52K | 60.39M | 30.88M | 19.10M | 9.86M |
| General & Administrative | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00K |
| SG&A | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.13M |
| Other Expenses | 0.00 | 2.86M | 19.80K | 280.00 | 2.56M | -821.00K | 37.00K | 0.00 |
| Operating Expenses | 194.21M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.00M |
| Cost & Expenses | 179.35M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.22M |
| Interest Income | 0.00 | 6.37M | 3.36M | 3.51M | 1.55M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.67M | 6.37M | 3.36K | 3.51K | 3.55M | 1.80M | 558.00K | 0.00 |
| Depreciation & Amortization | 5.61M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 676.00K | 220.00K |
| EBITDA | -109.04M | -54.77M | -117.06M | -145.48M | -91.68M | -45.12M | -20.88M | -5.12M |
| EBITDA Ratio | -168.52% | -43.79% | -389.32% | 0.00% | 0.00% | 0.00% | -699.50% | -53.53% |
| Operating Income | -129.50M | -59.95M | -141.41K | -126.55K | -85.53M | -41.99M | -19.67M | -5.45M |
| Operating Income Ratio | -200.15% | -45.98% | -452.69% | 0.00% | 0.00% | 0.00% | -658.89% | -55.78% |
| Total Other Income/Expenses | 6.18M | -3.51M | 16.44M | -129.65M | -7.68M | -2.62M | 1.40M | 109.00K |
| Income Before Tax | -123.32M | -63.46M | -124.97K | -129.78K | -86.53M | -44.61M | -20.19M | -5.34M |
| Income Before Tax Ratio | -190.60% | -48.68% | -400.07% | 0.00% | 0.00% | 0.00% | -676.35% | -54.67% |
| Income Tax Expense | 107.00K | 544.00K | -4.53M | -2.58M | 6.11M | -202.00K | -527.00K | -765.00K |
| Net Income | -123.43M | -64.00M | 4.40M | 2.45M | -92.64M | -44.40M | -19.66M | -4.58M |
| Net Income Ratio | -190.76% | -49.10% | 14,097.81% | 0.00% | 0.00% | 0.00% | -658.69% | -46.84% |
| EPS | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| EPS Diluted | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| Weighted Avg Shares Out | 90.19M | 71.91M | 62.18M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
| Weighted Avg Shares Out (Dil) | 90.19M | 71.95M | 62.24M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful
Source: https://incomestatements.info
Category: Stock Reports